expect guidanc bracket consensu pharma op inc
growth come respect also see potenti upsid
due y/i bp improv gener price think investor
focus opioid litig light report possibl settlement would bring
final issu
expect adj ep guidanc bracket consensu analysi indic
rang rel consensu base
assumpt y/i pharmaceut distribut adj oper incom growth
y/i servic adj oper incom growth expect
guid y/i adj oper incom growth
distribut base normal adj oper incom grow estim
y/i exclud certain non-recurring headwind tailwind note see
potenti upsid estim management includ increment contribut
pharmedium expect guid y/i adj oper incom growth
servic base assumpt issu relat
fusion implement lash rectifi lash return growth
profit recal without headwind due fusion implement servic
adj oper incom growth would double-digit assum
repurchas common share
estim adj ep line consensu see
potenti upsid pharmaceut distribut segment consider
improv gener price rel compar quarter last year similar
last two quarter recal pharmaceut distribut result came
better expect believ primarili due moder gener
inflat gener price analysi indic gener inflat qtd august
compar gener deflat bp improv
wall street journal wsj report distributor talk
collect pay year settl opioid litig possibl settlement
also report new york time reuter believ fact
multipl news sourc report possibl settlement indic discuss
progress expect may forthcom addit
figur durat cite articl true think settlement would
attract drug distributor hang all-encompass
broad resolut
maintain adj ep estim slightli lower adj ep
estim maintain pt base revis dcf
analysi impli share trade adj ep estim
pleas see page report import disclosur
posit believ share trade attract multipl particularli
fundament core pharma distribut stabil also view
lead posit specialti favor addit see potenti upsid
pharmedium acceler growth segment beyond mwi
lash expect becom meaning contributor
resolut opioid litig
updat strateg financi
review pharmedium
top-lin growth driven
specialti includ alliancerx
acquisit hd smith store
acquir
gross margin
ebit margin
top-lin growth high-singl digit
due greater expect growth
gm due moder
gener deflat
sg better expect due
share come lower due greater
expect share repo
top-lin growth low-singl digit
due lower brand inflat
margin closer due higher
expect gener deflat lower
expect brand inflat
sg come wors expect
share come higher due lower
expect share repo
one three largest pharmaceut distribut compani
 servic pharmaceut manufactur health care provid
pharmaceut suppli channel primarili provid drug distribut relat servic
distribut comprehens offer brand name gener pharmaceut over-the-
counter health care product home health care suppli equip wide varieti
health care provid locat throughout includ acut care hospit
health system independ chain retail pharmaci mail-ord facil physician
clinic altern site facil skill nurs assist live center
expect adj ep guidanc bracket consensu analysi
indic rang rel consensu figur
base assumpt y/i pharmaceut distribut adj oper
incom growth y/i servic adj oper incom growth
assum debt paydown million result declin
interest expens million million assum tax rate
base initi tax rate guidanc assum
repurchas billion common share lower weight averag share
million million note capit
deploy could result upsid estim
million
cowen compani
expect guid y/i adj oper incom growth
pharmaceut distribut base estim normal adj
oper incom grow pharmaceut distribut y/i exclud
certain non-recurring headwind tailwind figur normal
pharmaceut distribut adj oper incom growth exclud increment
contribut acquisit smith store acquir
pharmerica contract exclud increment headwind relat pharmedium
moder brand inflat normal flu season rel
note normal estim doesnt exclud increment contribut
favor gener price environ expect dissip earli
anniversari given difficulti quantifi benefit addit
see potenti upsid estim manag includ increment
contribut pharmedium
y/i y/i oper interest assum debt paydownpre-tax incom effect tax initi guidancenet net incom attribut net incom attribut wtd average assum share repoadj rel cowen
million
cowen compani
million
cowen compani
expect guid y/i adj oper incom growth
servic acceler guidanc high-singl digit percentag growth
base assumpt issu relat fusion implement
lash rectifi lash return growth profit expect
transit year lash manag continu excit
long-term outlook busi recal without headwind due fusion
implement servic adj oper incom growth wouldv
led strong perform mwi anim servic note last quarter
segment see nice growth across busi
estim adj ep in-line consensu see
potenti upsid pharmaceut distribut segment
consider improv gener price rel compar quarter last
year similar last two quarter recal pharmaceut distribut
result came better expect believ primarili due
moder gener inflat figur gener price analysi indic gener
inflat quarter-to-d august compar gener deflat
bp improv gener price y/i figur
oper profit store acquir brand inflat oper profit ex-nonrecur y/i op inc smith storesacquir bywbapharmericapharmediumbrandinflationmoderationflunormalizedop inc cowen
compani report streetaccount cowen compani
note data quarter-to-d august
iqvia cowen compani
wall street journal wsj report drug distributor
talk collect pay billion year settl opioid litig brought forth
state local govern possibl settlement also report
new york time reuter believ fact multipl news sourc
report possibl settlement indic discuss progress
expect may forthcom addit figur durat cite
articl true think settlement would attract drug
distributor hang all-encompass broad resolut
settlement encompass believ must least cover vast
major pend opioid lawsuit provid visibl liabil
remain lawsuit distributor agre settlement recal
distributor previous convey market prefer outcom
all-encompass univers settlement proport believ
role opioid epidem addit billion year would result
approxim per year three distributor next year
think manag would view favor street
would assum would financ settlement via debt given leverag ratio
current stand
expect manag provid updat regard pharmedium particularli
regard on-going third-parti audit inspect two open facil result
input assess futur work plan reopen
memphi facil enter consent decre complet initi third-
parti order inspect meaning mileston pharmedium continu
on-going comprehens strateg financi review busi also look
anyth increment volum could look like pharmedium fulli
oper given manag previou comment difficult
pharmedium volum return previou level next year led
maintain adj ep estim slightli lower adj ep
estim addit rais price target
base revis dcf analysi impli share trade
adj ep estim
million except per-shar data
cowen compani
model assumptionstermin growth depreci chang work capit valuefre free futur excess number per end septemb cowen
million except per-shar data
compani report cowen compani
cost good gross margin ebitda ebit losses/ incom affili exp tax incom conv sub note deal-rel sever litig incom cont incom deal-rel incom ex-discontinu average ep ex discontinu chang incom cont ep cont end septemb cowen
million except per-shar data
compani report cowen compani
cost good gross margin ebitda ebit losses/ incom affili exp tax incom conv sub note deal-rel sever litig own net incom deal-rel incom ex-discontinu average ep ex-discontinu chang year-over-year total incom cont ep cont cowen
million
compani report cowen compani
asset receiv net doubt expens current charg total liabil account payabl incom current equiti common paid-in earn comprehens commmon stock total stockhold liabil stockhold liquid ratio current sale purchas acct ratio inventori structur long-term solvenc ratio total debt total interest ratio return commit capit asset averag stockhold equiti cowen
million
compani report cowen compani
income/ loss flow oper activ depreci provis loss account sale invest employe stock defer incom invest impair oper asset liabil account merchandis prepaid expens account payabl accru expens incom net cash oper acquisit properti acquisit purchas treasuri dividend common proceeds/ repay debt net increase/ decreas cash equival begin cash equival end summari oper year end septemb cowen
million
compani report cowen compani
activitiesnet loss incom discontinu incom continu adjust reconcil net incom provis loss account provis defer incom employe stock loss dispos properti equipment- impair charg equiti investment- lifo pension settlement- includ intang asset loss earli retir chang oper asset liabil account merchandis prepaid expens account payabl accru expens incom net cash provid use oper activ continu net cash provid use oper activ discontinu net cash provid use oper invest activitiescapit acquir compani net cash proce sale properti equipment- equiti proce sale business- purchas invest secur avail sale- net cash provid use invest activ continu net cash provid use invest activ discontinu ops- net cash provid use invest financ activitiesborrow revolv securit credit purchas treasuri payment premium earli retir debt- defer financ cost other- exercis warrants- exercis stock dividend common purchas cap call net cash provid use financ activ continu net cash provid use financ activ discontinu op net cash provid use financ increas cash cash cash equival begin cash equival end fiscal year end septemb cowen
use five-year discount cash flow analysi primari valuat method
deriv price target gener assum discount rate may appli
appropri adjust depend compani and/or industri specif factor also
assum termin growth rate depend long-term view specif
sub-industri coverag note discount rate assumpt could view
conserv rel actual weight averag cost capit view
assumpt reason long run lower discount rate assumpt
increas termin growth rate assumpt would lead higher estim valu
per share secondari measur look forward price-to-earnings multipl ev/sal ratio
impli dcf analysi compar histor averag
potenti risk associ drug distribut space industri
highli competit could pressur margin core drug distribut busi
current wave drug patent expir posit impact profit
deriv gener expect taper significantli next sever year
specialti provid signific tailwind industri concern
around sustain high growth biotech sector longer term
impact ppaca expect increas volum could subdu depend
implement execut
number company-specif risk associ pt includ credibl
indic enter pharma suppli chain sharp unexpect declin
gener deflat less expect benefit wbad econodisc
